Accessibility Menu
RemeGen logo

RemeGen(OTC) REGMF

Market Cap$6.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-30%
5 Year-30%
1 Year+116%
1 Month-5%
$10.93
+7.16%
+0.73Today
RemeGen last closing stock price
MetricPriceDate
Last closeUSD 10.932026-08-28
RemeGen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.87%USD 11.492026-07-16
1 month-4.87%USD 11.492026-07-16
3 month-9.29%USD 12.052026-05-15
Year to date+11.42%USD 9.812025-12-26
1 year+116.01%USD 5.062025-08-27
3 year+173.25%USD 4.002023-07-05
5 year-30.07%USD 15.632021-01-21
Since inception-30.07%USD 15.632021-01-21

RemeGen Financials at a Glance

Market Cap

$6.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥7.95B

Net Income (TTM)

CN¥5.78B

EPS (TTM)

$1.51

P/E Ratio

7.22

Dividend

$0.00

Beta (Volatility)

0.06 (Low)

Price

$10.93

Volume

400

Open

$10.73

Previous Close

$10.93

Daily Range

$10.73 - $10.93

52-Week Range

$5.06 - $15.91

Estimated Earnings Date

Nov 4, 2026

REGMF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About RemeGen

RemeGen Co., Ltd. is a biopharmaceutical company based in Yantai, China, established in 2008. The firm specializes in the discovery, development, and commercialization of biologics aimed at addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases.

Products and Services
  • Telitacicept (RC18) for systemic lupus erythematosus
  • Disitamab Vedotin (RC48) for various cancers
  • Robust pipeline including candidates for multiple diseases
Growth Outlook
  • Telitacicept is in Phase III trials for neuromyelitis optica spectrum disorder
  • RC28 has completed Phase I trials for wet age-related macular degeneration
  • Multiple candidates in preclinical stages targeting solid tumors
Financial Highlights
  • Q2 2026 revenue of 5.18 billion CNY, a significant increase
  • Net income for Q2 2026 reached 4.32 billion CNY
  • Strong gross profit margin of 96.53% in Q2 2026
RemeGen Co., Ltd. has demonstrated a strong financial performance, particularly in the second quarter of 2026, with a revenue of 5.18 billion CNY, reflecting a robust growth trajectory. The net income for the same period reached 4.32 billion CNY, showcasing the company's ability to convert revenue into profit effectively. The gross profit margin of 96.53% indicates efficient cost management and a strong market position. The ongoing clinical trials and a diverse product pipeline further enhance the company's potential for future growth, making it an intriguing option for investors interested in the biotechnology sector.
AI Generated • Sep 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,048

CEO

Jian Min Fang, PhD

Website

www.remegen.com

Headquarters

Yantai, SD, CN

REGMF Financials

Key Financial Metrics (TTM)

Gross Margin

92.67%

Operating Margin

61.01%

Net Income Margin

72.70%

Return on Equity

128.12%

Return on Capital

2.18%

Return on Assets

59.11%

Earnings Yield

13.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

558.40M

Volume

400

Avg. Volume

53.266

Financials (TTM)

Gross Profit

CN¥7.37B

Operating Income

CN¥4.86B

EBITDA

CN¥5.02B

Operating Cash Flow

CN¥4.50B

Capital Expenditure

-CN¥155.26M

Free Cash Flow

CN¥4.35B

Cash & ST Invst.

CN¥5.14B

Total Debt

CN¥311.01M

RemeGen Performance Analysis

RemeGen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 114,608,356-48.2%
20232023-12-31CNY 152,716,49433.3%
20242024-12-31CNY 237,626,14355.6%
20252025-12-31CNY 452,057,09790.2%
RemeGen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.9%
Q42025-12-31144.5%
Q12026-03-31-56.9%
Q22026-06-30696.4%
RemeGen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.28N/A
20232023-12-31CNY -0.4042.0%
20242024-12-31CNY -0.38-4.3%
20252025-12-31CNY 0.18N/A
RemeGen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3051.4%
Q42025-12-311361.1%
Q12026-03-31-74.4%
Q22026-06-301222.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥5.18B

+804.9%

Gross Profit

CN¥5.00B

+930.2%

Gross Margin

96.53%

N/A

Market Cap

$6.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.00M

N/A

Employees

3,048

N/A

Net Income

CN¥4.32B

+2308.8%

EBITDA

CN¥4.45B

+4320.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥5.14B

+300.9%

Total Debt

CN¥311.01M

-88.4%

Accounts Receivable

CN¥619.46M

+10.3%

Inventory

CN¥758.62M

+18.3%

Long Term Debt

CN¥88.01M

-89.6%

Short Term Debt

CN¥223.00M

-87.8%

Return on Assets

59.11%

N/A

Return on Invested Capital

57.56%

N/A

Free Cash Flow

CN¥4.16B

+3025.4%

Operating Cash Flow

CN¥4.19B

+7418.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SHTDYSinopharm Group Co. Ltd.
$9.83+1.02%
TRSBF3SBio Inc.
$2.15+0.00%
KYKOFKyowa Kirin Co., Ltd.
$15.80+9.53%
ZLDPFZealand Pharma A/S
$47.64+0.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About REGMF

What is the current price of RemeGen?

RemeGen is trading at $10.93 per share.

What is the 52-week range for RemeGen?

Over the past 52 weeks, RemeGen has traded between $5.06 and $15.91.

How much debt does RemeGen have?

As of the most recent reporting period, RemeGen reported total debt of CN¥45.84M.

How much cash does RemeGen have on hand?

RemeGen reported CN¥228.77M in cash and cash equivalents in its most recent financial results.

What is RemeGen’s dividend yield?

RemeGen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services